Obicetrapib Monotherapy
Heterozygous Familial Hypercholesterolemia (HeFH)
Key Facts
About NewAmsterdam Pharma
NewAmsterdam Pharma's mission is to develop innovative oral therapies for cardiovascular and lipid-related diseases, targeting the large population of patients failing to achieve LDL-C goals. Its core achievement is the late-stage development of obicetrapib, a CETP inhibitor with compelling Phase 3 efficacy and safety data, supported by over $1.2 billion in total capital raised. The company's strategy involves securing regulatory approval, preparing for a U.S. launch, and leveraging ex-U.S. partnerships like the one with Menarini Group to maximize global commercial potential.
View full company profileAbout NewAmsterdam Pharma
NewAmsterdam Pharma's mission is to develop innovative oral therapies for cardiovascular and lipid-related diseases, targeting the large population of patients failing to achieve LDL-C goals. Its core achievement is the late-stage development of obicetrapib, a CETP inhibitor with compelling Phase 3 efficacy and safety data, supported by over $1.2 billion in total capital raised. The company's strategy involves securing regulatory approval, preparing for a U.S. launch, and leveraging ex-U.S. partnerships like the one with Menarini Group to maximize global commercial potential.
View full company profile